Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: The Women, Integrase and Fat Accumulation Trial

HIV Medicine

Volumn 15, Issue 7, 2014, Pages 431-441

  Lake, Je ^a   Mccomsey, G A ^b   Hulgan, T ^c   Wanke, C A ^d   Mangili, A ^d   Walmsley, S L ^e   Stramotas, S A ^f   Tracy, R ^g   Currier, J S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF VERMONT   (United States)

Author keywords

Inflammation; Monocyte activation; Raltegravir; sCD14; Women

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR PLUS RITONAVIR; C REACTIVE PROTEIN; CD14 ANTIGEN; CD163 ANTIGEN; CHOLESTEROL; D DIMER; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; FATTY ACID BINDING PROTEIN; FOSAMPRENAVIR; FOSAMPRENAVIR PLUS RITONAVIR; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; SOLUBLE CD14 ANTIGEN; TENOFOVIR; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VIRUS RNA; 2 PYRROLIDONE DERIVATIVE; BIOLOGICAL MARKER; INTEGRASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AFRICAN AMERICAN; ARTICLE; ASIAN; BODY MASS; CAUCASIAN; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DRUG SUBSTITUTION; ETHNICITY; EXPLORATORY RESEARCH; FEMALE; GLUCOSE BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIP CIRCUMFERENCE; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERLIPIDEMIA; INTRAABDOMINAL FAT; LIPID STORAGE; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TOBACCO USE; WAIST CIRCUMFERENCE; WAIST HIP RATIO; ABDOMINAL FAT; HIV INFECTIONS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; VIROLOGY;

ABDOMINAL FAT; ADIPOSITY; ADULT; ANTIGENS, CD14; BIOLOGICAL MARKERS; DRUG SUBSTITUTION; FEMALE; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; MIDDLE AGED; OVERWEIGHT; PYRROLIDINONES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL;

EID: 84904037791     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12128     Document Type: Article

References (48)

1. Baker JV, Neuhaus J, Duprez D etal. Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr 2011; 56: 36-43.
2. Brown TT, Tassiopoulos K, Bosch RJ, Shikuma C, McComsey GA. Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care 2010; 33: 2244-2249.
3. Hileman CO, Wohl DA, Tisch DJ, Debanne SM, McComsey GA. Short communication: initiation of an abacavir-containing regimen in HIV-infected adults is associated with a smaller decrease in inflammation and endothelial activation markers compared to non-abacavir-containing regimens. AIDS Res Hum Retroviruses 2012; 28: 1561-1564.
4. Neuhaus J, Jacobs DR, Jr, Baker JV etal. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201: 1788-1795.
5. McComsey GA, Kitch D, Daar ES etal. Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir. AIDS 2012; 26: 1371-1385.
6. Kuller LH, Tracy R, Belloso W etal. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5: e203.
7. Sandler NG, Wand H, Roque A etal. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203: 780-790.
8. Boulware DR, Hullsiek KH, Puronen CE etal. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis 2011; 203: 1637-1646.
9. Ranoa DR, Kelley SL, Tapping RI. Human lipopolysaccharide-binding protein (LBP) and CD14 independently deliver triacylated lipoproteins to toll-like receptor 1 (TLR1) and TLR2 and enhance formation of the ternary signaling complex. J Biol Chem 2013; 288: 9729-9741.
10. Kirkland TN, Viriyakosol S. Structure-function analysis of soluble and membrane-bound CD14. Prog Clin Biol Res 1998; 397: 79-87.
11. Ogawa Y, Imajo K, Yoneda M etal. Soluble CD14 levels reflect liver inflammation in patients with nonalcoholic steatohepatitis. PLoS One 2013; 8: e65211.
12. Mendez-Lagares G, Romero-Sanchez MC, Ruiz-Mateos E etal. Long-term suppressive combined antiretroviral treatment does not normalize the serum level of soluble CD14. J Infect Dis 2013; 207: 1221-1225.
13. Wallet MA, Rodriguez CA, Yin L etal. Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy. AIDS 2010; 24: 1281-1290.
14. Merlini E, Bai F, Bellistri GM, Tincati C, d'Arminio Monforte A, Marchetti G. Evidence for polymicrobic flora translocating in peripheral blood of HIV-infected patients with poor immune response to antiretroviral therapy. PLoS One 2011; 6: e18580.
15. Thiebaut R, Charpentier C, Damond F etal. Association of soluble CD14 and inflammatory biomarkers with HIV-2 disease progression. Clin Infect Dis 2012; 55: 1417-1425.
16. Justice AC, Freiberg MS, Tracy R etal. Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV? Clin Infect Dis 2012; 54: 984-994.
17. Romero-Sanchez M, Gonzalez-Serna A, Pacheco YM etal. Different biological significance of sCD14 and LPS in HIV-infection: importance of the immunovirology stage and association with HIV-disease progression markers. J Infect 2012; 65: 431-438.
18. Lake JE, McComsey GA, Hulgan TM etal. A randomized trial of raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy. AIDS Patient Care STDS 2012; 26: 532-540.
19. Asmuth DM, Ma ZM, Mann S etal. Gastrointestinal-associated lymphoid tissue immune reconstitution in a randomized clinical trial of raltegravir versus non-nucleoside reverse transcriptase inhibitor-based regimens. AIDS 2012; 26: 1625-1634.
20. Manner I, Baekken M, Kvale D etal. Markers of microbial translocation predict hypertension in HIV-infected individuals. HIV Med 2013; 14: 354-361.
21. Kelesidis T, Kendall MA, Yang OO, Hodis HN, Currier JS. Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection. J Infect Dis 2012; 206: 1558-1567.
22. Merlini E, Luzi K, Suardi E etal. T-cell phenotypes, apoptosis and inflammation in HIV+ patients on virologically effective cART with early atherosclerosis. PLoS ONE 2012; 7: e46073.
23. Subramanian S, Tawakol A, Burdo TH etal. Arterial inflammation in patients with HIV. JAMA 2012; 308: 379-386.
24. Blodget E, Shen C, Aldrovandi G etal. Relationship between microbial translocation and endothelial function in HIV infected patients. PLoS ONE 2012; 7: e42624.
25. Lyons JL, Uno H, Ancuta P etal. Plasma sCD14 is a biomarker associated with impaired neurocognitive test performance in attention and learning domains in HIV infection. J Acquir Immune Defic Syndr 2011; 57: 371-379.
26. Burdo TH, Weiffenbach A, Woods SP, Letendre S, Ellis RJ, Williams KC. Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection. AIDS 2013; 27: 1387-1395.
27. Ancuta P, Kamat A, Kunstman KJ etal. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS ONE 2008; 3: e2516.
28. Patterson KB, Prince HA, Stevens T etal. Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure. AIDS 2013; 27: 1413-1419.
29. Hatano H, Strain MC, Scherzer R etal. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis 2013; 208: 1436-1442.
30. Buzon MJ, Massanella M, Llibre JM etal. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010; 16: 460-465.
31. McMahon D, Jones J, Wiegand A etal. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis 2010; 50: 912-919.
32. Besson GJ, McMahon D, Maldarelli F, Mellors JW. Short-course raltegravir intensification does not increase 2 long terminal repeat episomal HIV-1 DNA in patients on effective antiretroviral therapy. Clin Infect Dis 2012; 54: 451-453.
33. Vallejo A, Gutierrez C, Hernandez-Novoa B etal. The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients. AIDS 2012; 26: 1885-1894.
34. Lam YM, McBride KL, Amin J etal. Switching virally suppressed, treatment-experienced patients to a raltegravir-containing regimen does not alter levels of HIV-1 DNA. PLoS ONE 2012; 7: e31990.
35. Byakwaga H, Kelly M, Purcell DF etal. Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial. J Infect Dis 2011; 204: 1532-1540.
36. Massanella M, Negredo E, Puig J etal. Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery. AIDS 2012; 26: 2285-2293.
37. Eron JJ, Young B, Cooper DA etal. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010; 375: 396-407.
38. Nseir W, Mahamid M. Statins in nonalcoholic fatty liver disease and steatohepatitis: updated review. Curr Atheroscler Rep 2013; 15: 305.
39. Bruckmeier M, Kuehnl A, Culmes M, Pelisek J, Eckstein HH. Impact of oxLDL and LPS on C-type natriuretic peptide system is different between THP-1 cells and human peripheral blood monocytic cells. Cell Physiol Biochem 2012; 30: 199-209.
40. Soumyarani VS, Jayakumari N. Oxidatively modified high density lipoprotein promotes inflammatory response in human monocytes-macrophages by enhanced production of ROS, TNF-alpha, MMP-9, and MMP-2. Mol Cell Biochem 2012; 366: 277-285.
41. Pelsers MM, Namiot Z, Kisielewski W etal. Intestinal-type and liver-type fatty acid-binding protein in the intestine. Tissue distribution and clinical utility. Clin Biochem 2003; 36: 529-535.
42. Vesterbacka J, Nowak P, Barqasho B etal. Kinetics of microbial translocation markers in patients on efavirenz or lopinavir/r based antiretroviral therapy. PLoS ONE 2013; 8: e55038.
43. Martinez E, D'Albuquerque PM, Llibre JM etal. Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS 2012; 26: 2315-2326.
44. Martin GE, Gouillou M, Hearps AC etal. Age-associated changes in monocyte and innate immune activation markers occur more rapidly in HIV infected women. PLoS ONE 2013; 8: e55279.
45. Hearps AC, Martin GE, Angelovich TA etal. Aging is associated with chronic innate immune activation and dysregulation of monocyte phenotype and function. Aging Cell 2012; 11: 867-875.
46. Hearps AC, Maisa A, Cheng WJ etal. HIV infection induces age-related changes to monocytes and innate immune activation in young men that persist despite combination antiretroviral therapy. AIDS 2012; 26: 843-853.
47. Zanni MV, Burdo TH, Makimura H, Williams KC, Grinspoon SK. Relationship between monocyte/macrophage activation marker soluble CD163 and insulin resistance in obese and normal-weight subjects. Clin Endocrinol (Oxf) 2012; 77: 385-390.
48. Koethe JR, Dee K, Bian A etal. Circulating interleukin-6, soluble CD14, and other inflammation biomarker levels differ between obese and nonobese HIV-infected adults on antiretroviral therapy. AIDS Res Hum Retroviruses 2013; 29: 1019-1025.